2026-04-13T02:29:16Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1837642025-12-05T11:56:55Zcom_2072_1057col_2072_478916col_2072_478917

00925njm 22002777a 4500 dc Archilla Ortega, Adrià author Domuro, Carla author Martin Liberal, Juan author Muñoz Moruno, Purificación author 2022-03-04T11:41:21Z 2022-03-04T11:41:21Z 2022-02-14 2022-03-03T12:38:12Z Immunotherapy has emerged as a promising strategy for boosting antitumoral immunity. Blockade of immune checkpoints (ICs), which regulate the activity of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells has proven clinical benefits. Antibodies targeting CTLA-4, PD-1, and PD-L1 are IC-blockade drugs approved for the treatment of various solid and hematological malignancies. However, a large subset of patients does not respond to current anti-IC immunotherapy. An integrative understanding of tumor-immune infiltrate, and IC expression and function in immune cell populations is fundamental to the design of effective therapies. The simultaneous blockade of newly identified ICs, as well as of previously described ICs, could improve antitumor response. We review the potential for novel combinatory blockade strategies as antitumoral therapy, and their effects on immune cells expressing the targeted ICs. Preclinical evidence and clinical trials involving the blockade of the various ICs are reported. We finally discuss the rationale of IC co-blockade strategy with respect to its downstream signaling in order to improve effective antitumoral immunity and prevent an increased risk of immune-related adverse events (irAEs). Immunoteràpia Cèl·lules T Immunotherapy T cells Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity